Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst Expectations
Analysts lowered Milestone Pharmaceuticals' fair value estimate by 13% due to more cautious views on Cardamyst launch execution.· summarised by Stockedin
YahooRead at the source
MIST